<div id="readability-page-1"><p><span>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report)</span> was downgraded by analysts at Citizens Jmp from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report issued on Monday,Briefing.com Automated Import reports.</p><p>A number of other equities research analysts also recently weighed in on the company. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, March 29th. Craig Hallum lowered their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, January 22nd. Finally, JMP Securities lowered their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a &#34;market outperform&#34; rating on the stock in a research note on Thursday, January 30th. Four analysts have rated the stock with a hold rating and four have issued  a buy rating to the company's stock. According to data from MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $8.60.</p><p><b>Check Out Our Latest Analysis on IRWD</b></p><h2>Ironwood Pharmaceuticals Trading Down 30.8 %</h2><p>NASDAQ:IRWD traded down $0.29 on Monday, hitting $0.65. 7,159,342 shares of the stock were exchanged, compared to its average volume of 2,469,602. Ironwood Pharmaceuticals has a fifty-two week low of $0.59 and a fifty-two week high of $8.45. The stock has a fifty day moving average of $1.55 and a 200-day moving average of $3.12. The stock has a market cap of $105.92 million, a PE ratio of -21.82 and a beta of 0.30. </p><p>Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.08). The firm had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.  As a group, analysts predict that  Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year. </p><h2>Insider Buying and Selling</h2><p>In other news, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders. </p><h2>Institutional Trading of Ironwood Pharmaceuticals</h2><p>Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in  Ironwood Pharmaceuticals during the fourth quarter worth approximately $36,000.  Journey Strategic Wealth LLC bought a new stake in shares of  Ironwood Pharmaceuticals during the 4th quarter worth $45,000.  Catalyst Funds Management Pty Ltd acquired a new position in  Ironwood Pharmaceuticals in the 4th quarter valued at $47,000.  Envestnet Asset Management Inc. bought a new position in  Ironwood Pharmaceuticals in the 4th quarter worth $50,000.  Finally, Xponance Inc. acquired a new position in  Ironwood Pharmaceuticals during the 4th quarter worth $50,000. </p><h2>About Ironwood Pharmaceuticals</h2> (Get Free Report)<p>Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Ironwood Pharmaceuticals</li><li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li><li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li><li>What to Know About Investing in Penny Stocks</li><li>3 Hot New IPOs Defying the 2025 Market Slump</li><li>2 Fintech Stocks to Buy Now and 1 to Avoid</li><li>3 High-Yield Dividend Stocks Trading at a Discount</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVJXRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ironwood Pharmaceuticals Right Now?</h2><p>Before you consider Ironwood Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ironwood Pharmaceuticals wasn't on the list.</p><p>While Ironwood Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IRWD

<p>Citizens Jmp downgraded Ironwood Pharmaceuticals (NASDAQ:IRWD) from "outperform" to "market perform" in a recent report. Other analysts have mixed views, with StockNews.com upgrading it to "buy" while Craig Hallum and JMP Securities lowered their target prices. The stock has seen a significant drop, trading down 30.8% to $0.65, with a market cap of $105.92 million. Recent insider trading shows CMO and CEO selling shares, and institutional investors have also made new stakes in the company. Ironwood focuses on gastrointestinal products, notably linaclotide for IBS treatment.</p>

Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by Citizens Jmp